The purpose of this study is to determine whether topiramate effective in treating dizziness
symptoms that are associated with migraine headaches.
Migraine is a common disorder, often associated with dizziness symptoms. In many cases,
dizziness is one of the only manifestations of migraine headaches. Various classes of drugs
have been advocated as treatment for migraine-associated dizziness, though none has been
shown to be superior over the others.
Topiramate is a drug approved for migraine prophylaxis. This study is designed to assess if
there are significant changes in dizziness frequency and severity in patients diagnosed with
migraine-associated dizziness treated with topiramate. Demonstrating benefit of topiramate
with a placebo-controlled study to alleviate symptoms of dizziness would serve to clarify
effective treatment options for patients with migraine-associated dizziness.
- Clinical diagnosis of migraine-associated dizziness.
- Previous or current use of topiramate prior to study enrollment.
- Need for continued use of the following medications for any medical reason during the
study: ergots, anti-epileptics, beta-blockers, calcium channel blockers, monoamine
oxidase inhibitors, high-dose magnesium, high-dose riboflavin, corticosteroids, local
anesthetics, botulinum toxin, or herbal preparations.
- History of nephrolithiasis.
- Women whom are pregnant or breastfeeding.
- Patients with known sensitivity to topiramate.
- Patients with a history of glaucoma.
- Patients with severe medical condition(s) that in the view of the investigator
prohibits participation in the study.